🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hepatocellular Carcinoma Identification Using Delta-HLD

Recruitingn/aAges 18 Years - 75 YearsAllEpiliquid Holding, Inc
NCT07148310 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls) * Willing and able to provide informed consent * Available paired plasma and liver tissue sample Exclusion Criteria: * Other active cancers * Prior liver transplantation * Known hereditary cancer syndromes * Recent chemotherapy or antiviral treatment (\<3 months)
💊

What it tests

  • Not listed
📍

Where

1 site
Epiliquid
Mendoza, Argentina
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy